Indications
Kimmtrak is indicated as monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
Composition
- Active substance
- tebentafusp
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Kimmtrak
- Active substance
- tebentafusp
- ATC code
- L01XX75
- Therapeutic area
- Uveal Neoplasms
- Marketing authorisation holder
- Immunocore Ireland Limited
- Status
- Authorised
- EU authorisation